Suven gets certificate of suitability for tamsulosin
This article was originally published in Scrip
Suven Life Sciences has received a certificate of suitability (CEP) from the European Directorate for the Quality of Medicines(EDQM) for its active pharmaceutical ingredient tamsulosin hydrochloride. Suven expects the CEP to simplify and ease the registration procedures for its customers. CEPs are recognised by member states of the EU and countries like Australia, Canada and Switzerland.